Wow, a game changer💥💥
GSK & Vir Submit EUA to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of #COVID19
COMET-TAIL Phase 3 data IM sotrovimab was non-inferior & offered similar efficacy to IV for high-risk populations
https://t.co/x23RNwfVNR
🆕🔥🔥🔥Clinical Practice Guideline @IDSAInfo@SHEA_Epi 2021 Focused Update Guidelines on Management of CDI in Adults
Major update💥:for patients with an initial CDI episode, guidelines suggest using fidaxomicin rather than a standard course of vancomycin https://t.co/2iqcoTHqLL
🔥🔥💥Pfizer BioNTech announced positive Topline Results of pivotal #COVID19 vaccine study in adolescents
Participants aged 12-15 years old, BNT162b2 demonstrated 100% efficacy and robust antibody responses💥🔥🔥
https://t.co/1HgnFRUBba
💥Excellent Summary💥 @NEJM
Results on SARS-CoV-2 Vaccine Trial Efficacy and Viral Neutralization of the B.1.1.7, P.1, and 501Y.V2 Variants, as Compared with Preexisting Variants.
With regard to escape from vaccine-induced immunity
https://t.co/bc4R2ohpBZ
Hi #IDtwitter,
@UnivHospNewark is actively recruiting for an ID Pharmacist!
Feel free to reach out to me with questions.
@SIDPharm crew, any bumps are appreciated! 🙌🏿↗️
https://t.co/jEY56K32uJ
With the Jan 7th announcement of the @remap_cap IL-6ra results: https://t.co/yophCZR40o
and last nights @BMJ_Latest RCT drop: https://t.co/lBTZ7lMBvH
let’s talk about tocilizumab [thread, 1/n]
🔥ACTIV-3 Published 🔥 @NEJM
Monoclonal antibody Bamlanivimab "LY-CoV555" , when coadministered with remdesivir, did NOT demonstrate efficacy among hospitalized patients who had #COVID19 without end-organ failure
https://t.co/UtZrH6O8Ke
Its been quite the year. Join @JulieSzymczak, @emilylheil, @zkePharmD, and @ErinMcCreary in our latest #Breakpoints episode for a discussion on stewardship burnout - what is it, who is at risk for it, and what can we do about it?
Find this and others at: https://t.co/QFVPqWUloG
There are currently four new cefepime/BLI combinations in clinical development
NEW 🔥fantastic review
Update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa #IDTwitter https://t.co/kEIYfchz5g
NEW🔥 @antibioticsmdpi@DosingMatters@lodise_tom
Use of Oral Tetracyclines "doxycycline, minocycline, and omadacycline" in the Treatment of Adult Patients with CAP: A Literature Review on the Often-Overlooked Antibiotic Class. #IDTwitter @mgh_ast
https://t.co/uM767YvbPq
@RealTimeCOVID19 clinical call notes
Summary from Jay Butler MD and Amanda Cohn MD after ACIP meeting
1. Separate monoclonal antibody and vaccine, at least 90 days
2. No switching between vaccines
3. Okay in pregnancy, no routine testing for pregnancy
✨✨Fantastic Review✨✨ @antibioticsmdpi
✴️Very important question✴️
Follow-Up Blood Cultures Useful in the Antimicrobial Management of Gram Negative Bacteremia? A Reappraisal of Their Role Based on Current Knowledge #IDTwitter https://t.co/a0LAdewpsw
🔔Breaking news🔔
ViiV Healthcare receives FDA Breakthrough Therapy Designation for investigational, long-acting cabotegravir for HIV prevention #IDTwitter HPTN 083
https://t.co/TIJENZB3t5